Inference of upstream-mutation and metabolomic-signature causality identifies prognostic biomarkers and therapeutic targets in pancreatic cancer
Feng Chen, Xiaoying Lou, Xingting Guo, Ye Guo, Yuan Huang, Kexin Li, Yan Song, Jiangtao Li, Jing Wang, Kai Lin, Ruijun Tian, Min Wang, Xudong Dai, Hezhi Fang, Wei Cui · 2026
Read Inference of upstream-mutation and metabolomic-signature causality identifies prognostic biomarkers and therapeutic targets in pancreatic cancer by Feng Chen, Xiaoying Lou, Xingting Guo, Ye Guo, Yuan Huang, Kexin Li, Yan Song, Jiangtao Li, Jing Wang, Kai Lin, Ruijun Tian, Min Wang, Xudong Dai, Hezhi Fang, Wei Cui (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13392447.txt.
Description
Feng Chen's team applied causal logic linking upstream gene changes to serum marker patterns in gut-gland ductal gland cancer. The cancer carries poor outlook and weak aimed-treatment response. Their Mutation-Upstream-of-Metabolomic-Signature approach tests whether blood markers capture cross-talk among gene-change-driven networks.
A nine-marker serum panel model life span across several cohorts, and analysis found GRPEL1 as a tumour-feeding gene whose energy-use-linked pattern meets mTOR, PI3K, and Akt signals. GRPEL1 softened cancer cells to growth halt under mTOR blocking, giving a system for new targets and reasoned combination therapies.
Catalog record
| CREATOR | Feng Chen, Xiaoying Lou, Xingting Guo, Ye Guo, Yuan Huang, Kexin Li, Yan Song, Jiangtao Li, Jing Wang, Kai Lin, Ruijun Tian, Min Wang, Xudong Dai, Hezhi Fang, Wei Cui |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 99 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |